Patents by Inventor Holger Faasch

Holger Faasch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6995272
    Abstract: The invention relates to a crystal modification of the compound of the formula I and the processes for the preparation of and use that crystal modifications 1. The invention is used for treating acute immunological episodes, such as sepsis, allergies, graft-versus-host and host-versus-graft-reactions, autoimmune diseases, in particular rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type II diabetes, liver fibrosis, cystic fibrosis, colitis, cancers, such as lung cancer, leukemia, ovarian cancer, sarcomas, Kaposi's sarcoma, meningioma, intestinal cancer, lymphatic cancer, brain tumors, breast cancer, pancreatic cancer, prostate cancer, or skin cancer.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: February 7, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Holger Faasch, Udo Hedtmann, Uwe Westenfelder, Erich Paulus
  • Patent number: 6900334
    Abstract: The invention relates to a crystal modification of the compound of the formula I and the processes for the preparation of and use that crystal modifications 1. The invention is used for treating acute immunological episodes, such as sepsis, allergies, graft-versus-host and host-versus-graft-reactions, autoimmune diseases, in particular rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type II diabetes, liver fibrosis, cystic fibrosis, colitis, cancers, such as lung cancer, leukemia, ovarian cancer, sarcomas, Kaposi's sarcoma, meningioma, intestinal cancer, lymphatic cancer, brain tumors, breast cancer, pancreatic cancer, prostate cancer, or skin cancer.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: May 31, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Holger Faasch, Udo Hedtmann, Uwe Westenfelder, Erich Paulus
  • Publication number: 20040204465
    Abstract: The invention relates to a crystal modification of the compound of the formula I 1
    Type: Application
    Filed: April 23, 2004
    Publication date: October 14, 2004
    Applicant: Aventis Pharma Deutschland GmbH.
    Inventors: Holger Faasch, Udo Hedtmann, Uwe Westenfelder, Erich Paulus
  • Publication number: 20030166945
    Abstract: The invention relates to a crystal modification of the compound of the formula I 1
    Type: Application
    Filed: November 25, 2002
    Publication date: September 4, 2003
    Applicant: Hoechst Marion Deutschland GmbH
    Inventors: Holger Faasch, Udo Hedtmann, Uwe Westenfelder, Erich Paulus
  • Patent number: 6552202
    Abstract: The invention relates to a crystal modification of the compound of the formula I and the processes for the preparation of and use that crystal modifications 1. The invention is used for treating acute immunological episodes, such as sepsis, allergies, graft-versus-host and host-versus-graft-reactions, autoimmune diseases, in particular rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type 11 diabetes, liver fibrosis, cystic fibrosis, colitis, cancers, such as lung cancer, leukemia, ovarian cancer, sarcomas, Kaposi's sarcoma, meningioma, intestinal cancer, lymphatic cancer, brain tumors, breast cancer, pancreatic cancer, prostate cancer, or skin cancer.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: April 22, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Holger Faasch, Udo Hedtmann, Uwe Westenfelder, Erich Paulus
  • Publication number: 20030027851
    Abstract: The invention relates to a crystal modification of the compound of the formula I 1
    Type: Application
    Filed: January 19, 2001
    Publication date: February 6, 2003
    Applicant: Hoechst Marion Deutschland GmbH
    Inventors: Holger Faasch, Udo Hedtmann, Uwe Westenfelder, Erich Paulus
  • Patent number: 6303792
    Abstract: The invention relates to a process for obtaining N-(4-trifluoromethylphenyl)-5-methyl-isoxazole-4-carboxamide in crystalline form, which is essentially free of byproducts. For this purpose, N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide is transferred into an organic solvent or into mixtures of organic solvents and water, the amount of byproduct in the solution is determined by quantitative analysis and an equimolar amount of a base is added. N-(4-Trifluoromethylphenyl)-5-methyl-isoxazole-4-carboxamide is isolated from the resulting solution by crystallization.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: October 16, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Hans-Hermann Lau, Udo Hedtmann, Holger Faasch, Andreas Gappisch
  • Patent number: 6221891
    Abstract: The invention relates to a crystal modification of the compound of the formula I and the processes for the preparation of and use that crystal modifications 1. The invention is used for treating acute immunological episodes, such as sepsis, allergies, graft-versus-host and host-versus-graft-reactions, autoimmune diseases, in particular rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type II diabetes, liver fibrosis, cystic fibrosis, colitis, cancers, such as lung cancer, leukemia, ovarian cancer, sarcomas, Kaposi's sarcoma, meningioma, intestinal cancer, lymphatic cancer, brain tumors, breast cancer, pancreatic cancer, prostate cancer, or skin cancer.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: April 24, 2001
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Holger Faasch, Udo Hedtmann, Uwe Westenfelder, Erich Paulus
  • Patent number: 6060494
    Abstract: The invention relates to a crystal modification of the compound of the formula I ##STR1## and the processes for the preparation of and use that crystal modifications 1. The invention is used for treating acute immunological episodes, such as sepsis, allergies, graft-versus-host and host-versus-graft-reactions, autoimmune diseases, in particular rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type II diabetes, liver fibrosis, cystic fibrosis, colitis, cancers, such as lung cancer, leukemia, ovarian cancer, sarcomas, Kaposi's sarcoma, meningioma, intestinal cancer, lymphatic cancer, brain tumors, breast cancer, pancreatic cancer, prostate cancer, or skin cancer.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: May 9, 2000
    Assignee: Hoechst Marion Roussel Deutschland GmbH
    Inventors: Holger Faasch, Udo Hedtmann, Uwe Westenfelder, Erich Paulus